Literature DB >> 33557271

Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma.

Claudia Wickenhauser1, Daniel Bethmann1, Matthias Kappler2, Alexander Walter Eckert2,3, André Steven4, Jürgen Bukur4, Bernard Aloysius Fox5, Jana Beer1, Barbara Seliger4,6.   

Abstract

Progression of oral squamous cell carcinoma (OSCC) has been associated with an escape of tumor cells from the host immune surveillance due to an increased knowledge of its underlying molecular mechanisms and its modulation by the tumor microenvironment and immune cell repertoire. In this study, the expression of HLA class I (HLA-I) antigens and of components of the antigen processing machinery (APM) was analyzed in 160 pathologically classified human papilloma virus (HPV)-negative OSCC lesions and correlated to the intra-tumoral immune cell response, IFN-γ signaling and to the patient's outcome. A heterogeneous but predominantly lower constitutive protein expression of HLA-I APM components was found in OSCC sections when compared to non-neoplastic cells. Tumoral HLA-I APM component expression was further categorized into the three major phenotypes HLA-Ihigh/APMhigh, HLA-Ilow/APMlow and HLA-Idiscordant high/low/APMhigh. In the HLA-Ihigh/APMhigh group, the highest frequency of intra-tumoral CD8+ T cells and lowest number of CD8+ T cells close to FoxP3+ cells were found. Patients within this group presented the most unfavorable survival, which was significantly evident in stage T2 tumors. Despite a correlation with the number of intra-tumoral CD8+ T cells, tumoral JAK1 expression as a surrogate marker for IFN-γ signaling was not associated with HLA-I/APM expression. Thus, the presented findings strongly indicate the presence of additional factors involved in the immunomodulatory process of HPV-negative OSCC with a possible tumor-burden-dependent complex network of immune escape mechanisms beyond HLA-I/APM components and T cell infiltration in this tumor entity.

Entities:  

Keywords:  HLA class I; antigen processing machinery; immune cell infiltration; immune escape; oral squamous cell carcinoma; prognosis

Year:  2021        PMID: 33557271      PMCID: PMC7914856          DOI: 10.3390/cancers13040620

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  53 in total

Review 1.  Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Authors:  Joshua D Horton; Hannah M Knochelmann; Terry A Day; Chrystal M Paulos; David M Neskey
Journal:  Trends Cancer       Date:  2019-03-20

Review 2.  Current status of oral cancer treatment strategies: surgical treatments for oral squamous cell carcinoma.

Authors:  Ken Omura
Journal:  Int J Clin Oncol       Date:  2014-04-01       Impact factor: 3.402

3.  Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Authors:  Sonja Ludwig; Theofanis Floros; Marie-Nicole Theodoraki; Chang-Sook Hong; Edwin K Jackson; Stephan Lang; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2017-04-11       Impact factor: 12.531

Review 4.  Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.

Authors:  Stefano Cavalieri; Licia Rivoltini; Cristiana Bergamini; Laura D Locati; Lisa Licitra; Paolo Bossi
Journal:  Cancer Treat Rev       Date:  2018-03-20       Impact factor: 12.111

5.  The head and neck cancer immune landscape and its immunotherapeutic implications.

Authors:  Rajarsi Mandal; Yasin Şenbabaoğlu; Alexis Desrichard; Jonathan J Havel; Martin G Dalin; Nadeem Riaz; Ken-Wing Lee; Ian Ganly; A Ari Hakimi; Timothy A Chan; Luc Gt Morris
Journal:  JCI Insight       Date:  2016-10-20

6.  Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.

Authors:  Stefani Spranger; Jason J Luke; Riyue Bao; Yuanyuan Zha; Kyle M Hernandez; Yan Li; Alexander P Gajewski; Jorge Andrade; Thomas F Gajewski
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-11       Impact factor: 11.205

7.  The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration.

Authors:  Francisco Perea; Mónica Bernal; Abel Sánchez-Palencia; Javier Carretero; Cristina Torres; Clara Bayarri; Mercedes Gómez-Morales; Federico Garrido; Francisco Ruiz-Cabello
Journal:  Int J Cancer       Date:  2016-11-07       Impact factor: 7.396

8.  HLA-A2 expression, stage, and survival in colorectal cancer.

Authors:  Philipp Kiewe; Veit Mansmann; Carmen Scheibenbogen; Heinz-Johannes Buhr; Eckhard Thiel; Dirk Nagorsen
Journal:  Int J Colorectal Dis       Date:  2008-05-07       Impact factor: 2.571

9.  Acquired resistance to immunotherapy and future challenges.

Authors:  Nicholas P Restifo; Mark J Smyth; Alexandra Snyder
Journal:  Nat Rev Cancer       Date:  2016-02       Impact factor: 60.716

10.  Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes.

Authors:  Sachet A Shukla; Michael S Rooney; Mohini Rajasagi; Grace Tiao; Philip M Dixon; Michael S Lawrence; Jonathan Stevens; William J Lane; Jamie L Dellagatta; Scott Steelman; Carrie Sougnez; Kristian Cibulskis; Adam Kiezun; Nir Hacohen; Vladimir Brusic; Catherine J Wu; Gad Getz
Journal:  Nat Biotechnol       Date:  2015-11       Impact factor: 54.908

View more
  3 in total

1.  An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer.

Authors:  Guian Zhang; Yong Luo
Journal:  Int J Gen Med       Date:  2021-11-30

Review 2.  24th "Nantes Actualités en Transplantation" and 4th "LabEx Immunotherapy-Graft-Oncology" NAT and IGO Joint Meeting "New Horizons in Immunotherapy".

Authors:  Noémie Joalland; Kathleen Ducoin; Gwenann Cadiou; Catherine Rabu; Carole Guillonneau
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

3.  The impact of tumor immunogenicity on cancer pain phenotype using syngeneic oral cancer mouse models.

Authors:  Nicole L Horan; Lisa A McIlvried; Megan A Atherton; Mona M Yuan; John C Dolan; Nicole N Scheff
Journal:  Front Pain Res (Lausanne)       Date:  2022-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.